INTRODUCTION
============

Osteoarthritis (OA) embodies a recurrent and incapacitating arthritic condition, characterized by the occurrence of damaging joint changes, including cartilage destruction by cytokines, matrix metalloproteinases and prostaglandins. As a consequence, a cascade of deleterious events starts, including subchondral bone remodeling and resorption, hypertrophic differentiation of chondrocytes, neovascularization of synovial tissue and focal joint cartilage calcification. Management of OA has been diverse and included pharmacological therapy treatment options, surgical interventions and orthopedic procedures including total joint replacement and/or joint fusion \[[@hnx011-B1], [@hnx011-B2]\].

Recent advances in regenerative medicine, particularly the optimization of procedures associated with the utilization of stem and progenitor cells, has opened new therapeutic perspectives for the treatment of OA. Given that articular cartilage exhibits little or no ability for self-repair, the option to delivery into the OA injured site a source of progenitor cells capable to differentiate into chondrocytes, appears to be an attractive therapeutic option \[[@hnx011-B3]\].

Mesenchymal stem cells (MSCs) fulfill the above requirements. In addition to differentiate into chondrocytes (which in turn produce and maintain a cartilaginous matrix), MSC produce and secrete a vast array of mediators of cell function, like growth factor and cytokines. And last but not least, the minute number of 'native' MSC present in several adult tissues, including the bone marrow, can be easily increased by *ex vivo* procedures \[[@hnx011-B7]\].

The study here presented was developed in an attempt to translate the cellular and molecular properties of MSC, into a feasible, safe and proficient therapeutic product aimed to restore the function of a damaged joint.

MATERIALS AND METHODS
=====================

Patient population
------------------

The study was performed at Clinica Las Condes, Santiago, Chile. Clinica Las Condes is affiliated to Johns Hopkins Medicine International and accredited by the Joint Commission International (USA). Procedures carried out in this study were in compliance with regulations established by the Research and Ethics Committees of Clinica Las Condes.

A total of 10 patients with osteoarthritis in one or both hips were enrolled in the study. Main inclusion criteria included age ≥ 60 years, radiological evidence of osteo-degenerative disease changes (level to moderate) in one or both joint hip (s) and pain levels (refractory to analgesics and/or hyaluronic acid or cortisone injection treatment) ≥ 40 (Visual Analog Scale of 100 mm).

Main exclusion criteria included evidence of intra-articular space ≤ 1 mm, indication of cartilage's loss of volume, as measured by magnetic resonance imaging and/or failure to complete the protocol's established number of cell infusions. Clinical characteristics of the study population are given in [Table I](#hnx011-T1){ref-type="table"}. Table I.Clinical characteristics of the study population at inclusionPatient characteristics (initials/sex/age)ComorbiditiesConcomitant drug(s) intakeHip damage locationRPB/f/57hypothyroidism, arrhythmia, arterial hypertensionAtenolol, Zopiclone LevothyroxinerightMMP/f/54hypothyroidism, cervical dysplasiaSyndol, TramadolrightDCF/m/60nonenonerightALH/m/50dyslipidemia, hypothyroidismLevothyroxinerightMOP/f/54hypothyroidism, asthma, arterial hypertensionLevothyroxine, Losartan, BudesoniderightPVV/f/51nonenonerightFVS/m/24nonenoneleftKOV/f/59asthma, arterial hypertension, dyslipidemiaAtenolol, Desloratadineright and leftJPD/m/49mood disorderSertralineright and leftSPS/m/39noneSibutramineright and left

Study end points
----------------

Primary endpoint included the feasibility to prepare from each patient a viable population of 60 × 10^6^*exvivo* expanded bone marrow-derived (BM)-MSC. Secondary endpoints included clinical evidence(s) confirming that the infusion of the cell product into the damaged hip(s) was safe and proficient to generate a slowdown in the progression of osteoarthritis.

Preparation of ex vivo expanded autologous BM-MSC
-------------------------------------------------

For preparation of BM-MSC, all patients underwent bone marrow aspiration (30 ml) from the posterior iliac crest. In the case of patients receiving BM-MSC infusion on both legs, the volume of bone marrow aspiration was 60 ml. Bone marrow aspirates were sent to the GMP facility for isolation and *ex vivo* expansion of bone marrow-resident MSC.

Shortly, the *ex vivo* expansion procedures included, (i) processing of bone marrow aspirates by density separation to isolate a fraction of mononuclear cells (BM-MNC), and b) the expansion, by means of cell culture procedures, of the minor population of 'native' MSC present in BM-MNC \[[@hnx011-B7], [@hnx011-B8]\]. At the end of the expansion procedures, the resulting population of autologous BM-MSC (the cell product) was assessed for cell number, viability, microbiological condition and expression of distinctive MSC cell membrane markers \[[@hnx011-B9]\]. In addition, flow cytometry analysis proved that the *ex vivo* manipulations did not triggered changes in MSC's attributes \[[@hnx011-B10]\].

Cell infusion
-------------

Before cell infusion, neither joint fluid was aspirated nor drugs injected in the hip joint. All anti-inflammatory or analgesic drugs were stopped at least 3--5 days before infusion.

Subsequently, the damaged hip (s) of each patient received the infusion of 20 × 10^6^*ex vivo* expanded BM-MSC. After 7 and 14 consecutive days, patients received the infusion of a second and a third dose of the respective cell product \[[@hnx011-B4], [@hnx011-B11]\]. Thus, within a period of 14 days, the damaged hip(s) of each patient received the infusion of 60 × 10^6^*ex vivo* expanded autologous MSC.

Clinical outcome assessment
---------------------------

Clinical data were prospectively collected during the study period (May 2013 to September 2016) and included evaluation of pain, stiffness, physical function and range of motion. For this, the following specific scores were used: Harris Hip (HHS), Visual Analog (VAS), Vail Hip and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Additionally, Tonnis X-ray measurements of the hip joint(s) were performed to evaluate changes in the progression of osteoarthritis \[[@hnx011-B5], [@hnx011-B11], [@hnx011-B12]\].

RESULTS
=======

Preparation and infusion of ex vivo expanded bone marrow-derived autologous MSC
-------------------------------------------------------------------------------

After bone marrow aspiration, no bleeding, infection and/or other complications were identified. In turn, *ex vivo* expanded autologous BM-MSCs manufactured for all patients, fulfilled the established rigorous release criteria for infusion \[[@hnx011-B9], [@hnx011-B10]\]. Accordingly, the infusion of the autologous cell product (three doses per damaged hip) was well tolerated and no complications and/or adverse events occurred post-infusion.

Clinical outcome
----------------

To assess whether the infusion of the cell product was beneficial patients were tested before and at different times after completing the cell infusion schedule. As shown in [Table II](#hnx011-T2){ref-type="table"}, raw data analysis using a cartilage injury evaluation package, indicated that in all patients the infusion of the cell product bring about an improvement in pain, function and range of motion during the follow-up period of 16--40 months after cell infusion. The statistical significance of the above data is shown in [Table III](#hnx011-T3){ref-type="table"}. In line with this observation, the radiographic scores (Tönnis Classification of Osteoarthritis) of the damaged leg(s) remained without variation in all patients, except one (SPS), after the administration of the cell product ([Table II](#hnx011-T2){ref-type="table"}). Table II.Clinical outcomes after MSC infusion by using a cartilage injury evaluation package including pain, function, range of motion and radiographic evaluationPatient[^a^](#tblfn1){ref-type="table-fn"}Leg treated[^b^](#tblfn2){ref-type="table-fn"}VASC[^c^](#tblfn3){ref-type="table-fn"}WOMAC[^d^](#tblfn4){ref-type="table-fn"}HHSM[^e^](#tblfn5){ref-type="table-fn"}VAIL[^f^](#tblfn6){ref-type="table-fn"}Tonnis[^g^](#tblfn7){ref-type="table-fn"}Last follow-up (months) after cell infusion)PrepostPrepostPrepostPrepostPrepostKOVL3021466985588II16R2010410788678II16SPSL42131369715555III22R11309510092100IIII22RPBR52705172834755IIII24ALHL61897472965586IIII27MMPR82513040754568IIII28PVVL42403263623442IIIIII29FVSL401210681006999IIII29MOPR53821436725676IIII30DCFR61341362836982IIII34JPDL20808210073100IIII40R401670965988IIIIII40[^1][^2][^3][^4][^5][^6][^7]Table III.Statistical significance of the clinical effects elicited by the infusion of*ex vivo* expanded autologous BM-MSC into patients with hip osteoarthritisHip scoresPre-infusion values (mean ± SEM)Post-infusion values (mean ± SEM)*P*-valueVAS4. 2 + 0.51.1 ± 0.30.0001WOMAC34. 5 ± 8.219.2 ± 6,10.15HHSM61, 9 ± 6.185.7 ± 3.90.003VAIL61 .2 ± 4.578.2 ± 5.20.02

DISCUSSION
==========

Several techniques, including micro fracture, autologous chondrocyte implantation, and mosaicplasty have been used for the treatment of symptomatic chondral lesions in the hip. Nevertheless, to date there is still no definitive solution to reproducibly replicate the load-bearing capacity and durability of native joint cartilage \[[@hnx011-B1], [@hnx011-B2], [@hnx011-B4]\]. Consequently, new therapeutic options based in the use of MSC have been initiated.

Even though strong evidences indicate that clinical use of MSC is feasible and safe \[[@hnx011-B4], [@hnx011-B5]\], confirmation for their clinical efficacy still remain controversial \[[@hnx011-B13]\].

The results presented in this clinical study, revealed that shortly after the intra articular infusion of a cell product consisting of *ex vivo* expanded autologous BM-MSC, an improvement in hip function occurred. The reparative effect, which is fully maintained over time ([Table II](#hnx011-T2){ref-type="table"}), proved to be free of major complications or side effects during the prolonged follow-up period. Moreover, the radiographic scores of the hip joint(s), assessed on a time period ranging from 7 to 30 months after cell infusion, clearly demonstrate a halt in the progression of osteoarthritis.

It seems likely that the distinctiveness of this clinical study, as compared to others \[[@hnx011-B3], [@hnx011-B15]\], may well reside in the two following attributes, (i) the *ex vivo* MSC expansion procedure employed in this study, privileged quality than quantity of cell product to be administered to the patient \[[@hnx011-B9], [@hnx011-B10]\], and (ii) based in previous observations, the cell product was administered to the patient, instead of 1 in 3 consecutive weekly doses \[[@hnx011-B4]\]. Further studies will contribute to validate and confirm the above statements.

We would like to acknowledge the dedicated contribution of clinicians researchers, and nurses at the Centro de Terapia Regenerativa Celular and Centro de Traumatología y Ortopedia, Clínica Las Condes, Santiago, Chile.

CONFLICT OF INTEREST STATEMENT
==============================

None declared.

[^1]: initials;

[^2]: L, left; R, right;

[^3]: pain scale;

[^4]: arthrosis level;

[^5]: hip function;

[^6]: hip function;

[^7]: radiographic evaluation.
